| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Faculty of Regional Professional Studies, Edith Cowen University, Bunbury and 2 Dept of Pulmonary Physiology, Sir Charles Gairdner Hospital, Nedlands, Western Australia
CORRESPONDENCE: N. Carroll, Faculty of Regional Professional Studies, Edith Cowen University, Robertson Drive, Bunbury, WA, 6230, Australia. Fax: 61 897807814. E-mail: n.carroll@ecu.edu.au
Keywords: asthma, mast cells, pathology
Received: August 23, 2001
Accepted November 27, 2001
This study was supported by the Asthma Foundation of Western Australia, National Health and Medical Research Council, Australia.
 |
Abstract |
|---|
 TOP Abstract MethodsResultsDiscussionReferences |
|---|
The density of mast cells (intact and degranulated) within airway compartments in cartilaginous and membranous airways, obtained from autopsies on patients with fatal asthma, nonfatal asthma, and nonasthmatic control cases have been examined.
In cartilaginous airways, the mean±se density of mast cells in control cases was 27±9 cells·mm–2. It was similar in nonfatal asthma (24±2 cells·mm–2) but reduced (p<0.05) in fatal asthma cases (16±2 cells·mm–2). In membranous airways, the density of mast cells in control cases was 155±21 cells·mm–2 and was higher (p<0.05) in cases of nonfatal (270±51 cells·mm–2) and fatal asthma (219±26 cells·mm–2). Mast-cell density was greatest on the smooth muscle and mucous glands in cartilaginous airways and on the smooth muscle and outer airway wall in membranous airways. The percentage of degranulated mast cells was higher (p<0.05) in cases of asthma, related to disease severity, and was higher in cartilaginous than membranous airways. Degranulation was greatest on the smooth muscle in fatal asthma cases.
Mast-cell distribution and degranulation varies between cartilaginous and membranous airways and across the airway wall. Degranulation of mast cells is related to asthma severity. The increased degranulation in proximal airways may reflect stimulation via the inhaled route.
Asthma is a disease characterized by airway inflammation 1 and remodelling 2. It has been suggested, but not proven, that inflammation results in remodelling.
The extent to which inflammatory cells interact with airway wall structures (which are subject to remodelling) depends on the distribution of inflammatory cells across the airway wall. Two studies 3, 4 have shown an increase in the numbers of mast cells found on the smooth muscle layer in isolated sensitized human bronchi compared with nonsensitized airways. Mast cells are present in varying numbers in patients with asthma 5–10. Their role in inflammatory reactions relates to their ability to store and release, or synthesize de novo, mediators of inflammation 11. The multiple actions of mast-cell derived mediators suggest that mast cells might interact with airway structures.
When mast cells are activated they become partly or completely degranulated 5. However, the extent to which this occurs in asthma and its relationship to disease severity has not been quantified. A further rationale for studying the distribution of inflammatory cells across the airway wall in large and small airways is to determine the degree to which assessing inflammation by sampling the proximal bronchial tree is representative of airway inflammation in the distal bronchial tree. Therefore, the aim of this study was to examine the distribution of mast cells and their degree of degranulation within the airway wall of the large and small airways of subjects without respiratory disease and compare them with patients with asthma.
|
Methods |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
Histological preparation
Lungs were fixed in formalin and transverse blocks of all large conducting airways down to the subsegmental level were cut, resulting in 12–18 large cartilaginous airways per case, from which five were randomly selected for this study. Six parenchymal sections (3x2x1 cm) were taken at random from the midsaggital slice of the lung. Tissue sections were cut (5 µm) and stained using the immunoperoxidase technique with the antimast cell tryptase monoclonal antibody AA1 (Dako Patts, Copenhagen, Denmark).
Airway dimensions
Airway dimensions (inner and outer airway wall thickness and areas of smooth muscle, submucosal mucous glands and cartilage) were measured as previously described 2. The basement membrane perimeter (Pbm) was directly traced using a camera lucida and a digitizing tablet.
Cell counts
Mast cells with a visible nucleus were counted and expressed as total number in each of the previously discussed compartments and cells·mm–2 of each compartment area (cell density). The percentage of total airway mast-cell count in each airway compartment was calculated.
Mast-cell degranulation
At high power (x400), positively-stained nucleated mast cells were classified as intact if they were dense, compact, had unbroken cytoplasmic boundaries and did not have any surrounding positively stained granules (fig. 1
). All other nucleated tryptase positive cells were classified as degranulated (fig. 2). Degranulated cells were expressed as a per cent of the total number of nucleated AA1-positive cells for the whole airway section and for each compartment.
|
|
Data analysis
The mean of each case group, calculated from the means of each case, was used for analysis. Bartlett's test for homogeneity of variances was performed. Where data was normally distributed, differences between groups were tested using parametric analysis (one way analysis of variance (ANOVA)) and where data was not normally distributed, nonparametric tests (Kruskal-Wallis nonparametric ANOVA) were used followed by Dunn's multiple comparison test. A probability value of <5% was considered significant.
|
Results |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
). The cases of nonfatal asthma were generally mild with infrequent symptoms.
|
).
|
).
Mast-cell density in airway wall compartments
Cartilaginous airways
Figure 3a shows mast-cell density in different airway wall compartments in cartilaginous airways. In control cases, the density of mast cells varied >50-fold across the airway wall, being highest on the smooth muscle (74±17 cells·mm–2), intermediate in the inner airway wall (35±3 cells·mm–2), submucosal glands (39±9 cells·mm–2) and outer airway wall (7±1 cells·mm–2) and was lowest in the epithelium (1.5±0.4 cells·mm–2) and lumen (0.2±0.1 cells·mm–2). In submucosal mucous glands, all mast cells were seen within the supporting stromal tissue surrounding glands and no cells were noted within individual serous or mucinous acini. Similar patterns were observed in the nonfatal and fatal cases of asthma. Compared with control cases, however, the density was significantly lower (p<0.05) in the smooth muscle, the inner airway wall and the epithelium of nonfatal and fatal cases. The density of mast cells in the lumen was higher (p<0.05) in the fatal cases compared with nonfatal cases of asthma, and both were higher than control cases (p<0.05). The density of mast cells on submucosal glands was significantly higher (p<0.05) in nonfatal compared with fatal cases of asthma and controls. In the outer airway wall there were no significant differences between the case groups.
|
shows mast-cell density in different airway wall compartments in membranous airways. In control cases, the highest density of mast cells was on the smooth muscle (201±27 cells·mm–2) and in the outer airway wall area (163±17 cells·mm–2). The density in the inner wall area (78±12 cells·mm–2), lumen (1±0.5 cells·mm–2) and epithelium (0.8±0.6 cells·mm–2) were significantly lower. In the nonfatal cases, the density of mast cells was significantly higher (p<0.05) on the smooth muscle and in both the inner and the outer airway wall areas compared with control cases. In the fatal cases, the density of mast cells was higher in the outer wall area, lumen and epithelium, compared with control cases. The overall density of mast cells in membranous airways was an order of magnitude higher than in the cartilaginous airways (table 2 and fig. 3a and b).
Per cent of total mast cells in different airway wall compartments
Cartilaginous airways
Figure 4a shows the per cent of total mast cells in different airway wall compartments in cartilaginous airways. Within the airway wall, the distribution of mast cells into the different compartments was similar in the three case groups except the submucosal mucous glands where the per cent of total mast cells was higher in the asthma cases. The highest percentages of mast cells were seen in both the inner and outer airway wall reflecting the greater area of these compartments on transverse section. In the epithelium, the per cent of mast cells was higher (p<0.05) in the control cases compared with the fatal and nonfatal asthma cases, whereas in the airway lumen, the per cent of mast cells was higher (p<0.05) in fatal than nonfatal asthma cases and control cases.
|
shows the per cent of total mast cells in different airway wall compartments in membranous airways. The greatest percentage of mast cells was observed in the outer airway wall, the largest compartment in membranous airways. In the cases of fatal asthma, the per cent of mast cells was higher (p<0.05) in the outer airway wall and airway lumen but was lower (p<0.05) in the inner airway wall and on the airway smooth muscle compared with control and nonfatal asthma cases. Fatal asthma and control cases had a higher per cent (p<0.05) of total mast cells in the epithelium than the cases of nonfatal asthma.
Degranulation
The average percentage of degranulated mast cells was higher (p<0.05) in cartilaginous airways than in membranous airways in all case groups. Compared with control cases, the percentage of degranulated mast cells was higher (p<0.05) in cases of nonfatal asthma and higher again in cases of fatal asthma (table 2). The differences in degranulation between the control and asthma case groups were similar in the different airway wall compartments, in both cartilaginous (fig. 5a) and membranous (fig. 5b) airways for the three case groups. However, degranulation was significantly higher on the airway smooth muscle mast cells in cases of fatal asthma compared with both control and nonfatal asthma cases.
|
|
Discussion |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
Mast-cell numbers in this study were expressed both as total numbers per transverse section and as density (the number of cells·mm–2 of area measured). This method of cell number estimation is a profile count of cells within a 3-dimensional (3D) structure and may be subject to bias if certain conditions are not met 12. Firstly, sampling of tissues and fields of interest for measurements need to be performed in a systematic random fashion. Secondly, all cells of interest must have an equal probability of being counted. This depends largely on cell size and orientation. Thirdly, the reference area for measurements (i.e. a 2-dimensional (2D) profile area) should be related to the 3D volume that the profile represents if absolute cell number in the airway volume are to be determined. In the present study, the sampling processes, from lung collection to individual airway blocks and sections, were systematic and random. Cells were identified using immunohistochemical staining but only counted if nucleated. The size of the mast-cell nucleus does not vary significantly 13 and is small compared with the reference section in which it was measured in this study. Because the authors were unable to define an initial reference volume for the whole lung, and did not use a "look-up" section, the 2D profile counts in this study could not be converted into a 3D volume estimate of absolute cell numbers. However, since nucleus size and orientation were not likely to have systematically changed between groups, the authors felt that these limitations would not affect comparisons between groups. Since measurement variability is predominantly due to subject and tissue-block variability 14, a large number of randomly-selected airways from different sites in the lung were examined and the mean data from each case was used to compare cell numbers between groups. Therefore, comparisons of relative cell densities between the groups in this study are valid and make the data directly comparable with the many other published studies that have reported cell numbers in this way.
Previous studies of mast-cell numbers in the airways have shown that compared with control cases, those with asthma have higher 5, 6, decreased 8, or similar 9, 10, 15, 16 numbers of mast cells. The variation between studies may be due to variations in asthma severity, use of different methodologies, effects of treatment and variations in the degree of degranulation 17–20. To the authors' knowledge, no previous studies have systematically quantified mast-cell degranulation. The higher concentrations of mast-cell derived mediators, such as histamine, prostaglandin D2 (PGD2), leukotriene C4 (LTC4) and tryptase seen in bronchoalveolar lavage (BAL) fluid in the early- and late-phase asthmatic reaction following local-allergen challenge 21, suggest mast-cell degranulation. The amount of degranulation was greatest in fatal asthma cases, suggesting increased mast-cell activation in these cases. In addition, increased degranulation may have caused underestimation of the number of mast cells in these cases (i.e. by not counting cells where there were no granules left).
The amount of mast-cell degranulation was found to be greatest in the submucosal mucous glands and on the airway smooth muscle layer in fatal asthma cases. Pesci et al. 22 showed an increase in the number of degranulated mast cells in the mucous glands of patients with chronic bronchitis, a disease characterized by excessive mucus production, and Bradding 11 observed that interleukin-6 positive mast cells are concentrated in close proximity to submucosal mucous glands 7. It is well documented that mast-cell derived proteases are capable of acting as potent secretagogues and that histamine, which is stored in and secreted from activated mast cells, stimulates smooth muscle shortening and vasodilatation 23. The authors have shown previously that increased secretion of mucus into the airway lumen combined with moderate amounts of smooth-muscle shortening in vivo, may give rise to exaggerated airway narrowing 24, which may contribute to sudden fatal asthma attacks 25. These findings suggest the mast cell to be an important effector cell during an acute attack of asthma.
The finding that the density of mast cells was highest on the smooth-muscle layer compared with other airway wall compartments is similar to the findings of Ammit et al. 3 and Berger et al. 4. The present study is the first quantitative evidence that mast cells are the predominant cell within the airway smooth-muscle layer in both nonasthmatics and asthmatics, and that those present on the smooth muscle layer in cases of fatal asthma are mostly degranulated. Connell 8 noted accumulation of mast cells near the smooth-muscle layer in cartilaginous bronchi from cases of fatal asthma. During an acute episode of asthma, activation of mast cells might cause abnormal release of chemical mediators, resulting in excessive stimulation of smooth muscle and mucous glands. This hypothesis is supported by the findings of elevated amounts of mast-cell derived mediators in BAL fluid from cases of asthma following allergen challenge 26 and lower numbers of mast cells in biopsies obtained from patients during an episode of asthma than during symptom-free periods 27.
One potential mechanism that may cause mast cell numbers in the airway wall to be reduced during asthma exacerbations is the movement of cells from the airway wall into the airway lumen. This is supported by the observation in this study of a higher percentage of mast cells in the lumen of fatal asthma cases compared with nonfatal asthma and nonasthmatic control cases. In addition, higher numbers of mast cells are observed in the sputum of atopic asthmatics after allergen-inhalation challenge 20. Another potential mechanism for reduced mast-cell numbers is increased apoptosis of cells. While the degree of mast-cell apoptosis was not assessed in this study and therefore cannot be excluded as a mechanism for reducing cell numbers, persistent inflammatory conditions are usually characterized by delayed or impaired apoptosis.
The degree of mast-cell degranulation in the present study was higher in the cartilaginous (proximal) airways compared with the membranous (distal) airways. It is tempting to speculate that a major reason for this is that the predominant stimulus for mast-cell degranulation occurs close to the mucosal surface of the airway and, to a greater extent, in the proximal bronchial tree, due to an inhaled stimulus. In the present study, the level of mast-cell degranulation in the mucous glands in all cases of asthma was significantly higher than that observed in the outer airway wall, suggesting selective stimulation of mast cells. A mechanism that may explain this, is the fact that neuropeptides are capable of inducing mast-cell degranulation 28 and there is an abundance of cholinergic nerves present in the airway epithelium that have local axonal pathways to submucosal mucous glands 29. Thus, stimulation of these nerves at the mucosal surface and subsequent release of neuropeptides may lead to increased mast-cell degranulation of mucous glands.
The density of mast cells was lower in the cartilaginous airways than the membranous airways in asthma cases compared with control cases. Similarly, the study of Connell 8 also reported decreased numbers of mast cells in the airway wall in cartilaginous airways from fatal asthma cases compared with control cases. Studies examining the numbers of mast cells in bronchial biopsies from the proximal bronchial tree in cases of mild asthma show variation, in that some studies show an increase in mast cells within the airway wall 5, 30, some in the epithelium only 6, and others showed no difference at all 9, 10, 15, 16. This variation may be due to degranulation, apoptosis or the effects of anti-inflammatory treatment. Nonetheless, the present study clearly demonstrates that bronchial biopsy obtained from the proximal bronchial tree may not always represent the pattern of inflammation across the airway wall or along the entire length of the bronchial tree.
In conclusion, in addition to their clearly defined role in immunoglobulin-E-dependent responses to antigenic stimulation in atopic disorders such as asthma, it is possible that mast cells may markedly amplify many features of the host response to nonspecific acute inflammatory stimuli, such as that seen in asthmatics in response to exercise, cold air and hypertonic saline inhalation. The separate activity of mast cells in the airways should be considered in both short-term and long-term treatment strategies.
|
References |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  M. Mellado, A. M. de Ana, L. Gomez, C. Martinez-A, and J. M. Rodriguez-Frade Chemokine Receptor 2 Blockade Prevents Asthma in a Cynomolgus Monkey Model J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 769 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Siddiqui, F. Hollins, S. Saha, and C. E. Brightling Inflammatory cell microlocalisation and airway dysfunction: cause and effect? Eur. Respir. J., December 1, 2007; 30(6): 1043 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Battaglia, T. Mauad, A. M van Schadewijk, A. M Vignola, K. F Rabe, V. Bellia, P. J Sterk, and P. S Hiemstra Differential distribution of inflammatory cells in large and small airways in smokers J. Clin. Pathol., August 1, 2007; 60(8): 907 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chhabra, Y-Z. Li, H. Alkhouri, A. E. Blake, Q. Ge, C. L. Armour, and J. M. Hughes Histamine and tryptase modulate asthmatic airway smooth muscle GM-CSF and RANTES release Eur. Respir. J., May 1, 2007; 29(5): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Begueret, P Berger, J M Vernejoux, L Dubuisson, R Marthan, and J M Tunon-de-Lara Inflammation of bronchial smooth muscle in allergic asthma Thorax, January 1, 2007; 62(1): 8 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Y. Green, J. C. Butt, A. L. James, and N. G. Carroll Abnormalities of the bronchial arteries in asthma. Chest, October 1, 2006; 130(4): 1025 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Carroll, N. G. Carroll, and A. L. James Do bronchial biopsies represent mast cell density in airways? A stereological study Eur. Respir. J., September 1, 2006; 28(3): 612 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Gounni The high-affinity IgE receptor (Fc{epsilon}RI): a critical regulator of airway smooth muscle cells? Am J Physiol Lung Cell Mol Physiol, September 1, 2006; 291(3): L312 - L321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Woodman, A. Sutcliffe, D. Kaur, M. Berry, P. Bradding, I. D. Pavord, and C. E. Brightling Chemokine Concentrations and Mast Cell Chemotactic Activity in BAL Fluid in Patients With Eosinophilic Bronchitis and Asthma, and in Normal Control Subjects. Chest, August 1, 2006; 130(2): 371 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Canonica Treating Asthma as an Inflammatory Disease Chest, July 1, 2006; 130(1_suppl): 21S - 28S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Brannan, M. Gulliksson, S. D. Anderson, N. Chew, J. P. Seale, and M. Kumlin Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing. Eur. Respir. J., May 1, 2006; 27(5): 944 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pang, M. Nie, L. Corbett, A. Sutcliffe, and A. J. Knox Mast Cell beta-Tryptase Selectively Cleaves Eotaxin and RANTES and Abrogates Their Eosinophil Chemotactic Activities J. Immunol., March 15, 2006; 176(6): 3788 - 3795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Tunon-de-Lara, P. Berger, and R. Marthan Chymase-positive Mast Cells: A Double-Edged Sword in Asthma? Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 647 - 648. [Full Text] [PDF]
|
|
|
|
|
|
S. Wenzel Severe Asthma in Adults Am. J. Respir. Crit. Care Med., July 15, 2005; 172(2): 149 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Fecteau, J.-C. Honore, M. Plante, J. Labonte, G. A. Rae, and P. D'Orleans-Juste Endothelin-1 (1-31) Is an Intermediate in the Production of Endothelin-1 After Big Endothelin-1 Administration In Vivo Hypertension, July 1, 2005; 46(1): 87 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Boyce and K. F. Austen No audible wheezing: nuggets and conundrums from mouse asthma models J. Exp. Med., June 20, 2005; 201(12): 1869 - 1873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mauad, L. F. F. Silva, M. A. Santos, L. Grinberg, F. D. C. Bernardi, M. A. Martins, P. H. N. Saldiva, and M. Dolhnikoff Abnormal Alveolar Attachments with Decreased Elastic Fiber Content in Distal Lung in Fatal Asthma Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 857 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Gelb, A. Schein, E. Nussbaum, C. M. Shinar, Y. Aelony, H. Aharonian, and N. Zamel Risk Factors for Near-Fatal Asthma Chest, October 1, 2004; 126(4): 1138 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Djukanovic, S. J. Wilson, M. Kraft, N. N. Jarjour, M. Steel, K. F. Chung, W. Bao, A. Fowler-Taylor, J. Matthews, W. W. Busse, et al. Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 583 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C E Brightling and I D Pavord Location, location, location: microlocalisation of inflammatory cells and airway dysfunction Thorax, September 1, 2004; 59(9): 734 - 735. [Full Text] [PDF]
|
|
|
|
|
|
S Baraldo, G Turato, C Badin, E Bazzan, B Beghe, R Zuin, F Calabrese, G Casoni, P Maestrelli, A Papi, et al. Neutrophilic infiltration within the airway smooth muscle in patients with COPD Thorax, April 1, 2004; 59(4): 308 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.M. Vignola, A. Bonanno, M. Profita, L. Riccobono, N. Scichilone, M. Spatafora, J. Bousquet, G. Bonsignore, and V. Bellia Effect of age and asthma duration upon elastase and {alpha}1-antitrypsin levels in adult asthmatics Eur. Respir. J., November 1, 2003; 22(5): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Subramaniam, K. Sugiyama, D. H. Coy, Y. Kong, Y. E. Miller, P. F. Weller, K. Wada, E. Wada, and M. E. Sunday Bombesin-like Peptides and Mast Cell Responses: Relevance to Bronchopulmonary Dysplasia? Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 601 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wenzel Severe/Fatal Asthma Chest, March 1, 2003; 123(2007): 405S - 410S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Tunon-de-Lara, P. Berger, H. Begueret, C. E. Brightling, P. Bradding, and I. D. Pavord Mast Cells in Airway Smooth Muscle N. Engl. J. Med., September 26, 2002; 347(13): 1040 - 1041. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||
: control; 
: nonfatal asthma cases; 
: fatal asthma cases. *: p<0.05 compared with control cases; #: p<0.05 compared with control and nonfatal cases; ¶: p<0.05 compared with control and fatal cases.
